Objective: Serum sex steroid concentrations may alter body composition and glucose homoeostasis in men in a dose-response manner. We evaluated these end-points in healthy men rendered medically castrate through use of a gonadotrophin-releasing hormone antagonist (acyline) with incremental doses of exogenous testosterone (T) gel.
changes produced by exogenous T on body composition and threshold sex steroid concentrations below which tissue-specific symptoms of hypogonadism might develop. 5 Similarly, dose-dependent effects of incremental doses of TRT have been shown in certain tissues. 6 However, whether these effects are direct or indirect, and whether they depend upon the dose of exogenous T given or the concentrations of its downstream metabolites, dihydrotestosterone (DHT) and/ or oestradiol (E2) achieved, has not been explored. This is particularly important in men receiving transdermal TRT, given variability in sex steroid concentrations achieved by this route.
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T is metabolized by 5α-reductase to produce DHT and by aromatase to E2. Although the roles DHT and E2 play in developing boys are well characterized, 8, 9 their importance in adult men is less clear.
Recent work has highlighted the importance of E2 in limiting adipose accumulation and maintaining sexual health in older men, 5 while studies utilizing inhibitors of 5α-reductase have demonstrated DHT is not required for androgenic effects on bone, muscle or adipose tissue in the presence of normal levels of circulating T.
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To understand how the administration of exogenous, transdermal T affects body composition, glucose homoeostasis and other cardiometabolic parameters, we performed a randomized, placebo-controlled intervention study in healthy men who were medically castrated with a
GnRH antagonist (acyline) and then received variable doses of topical T (ranging from subphysiological to supraphysiological). We hypothesized that lean mass would show dose-dependent increases with supraphysiological T doses, while fat mass would show dose-dependent decreases, and that the reverse would be observed with subphysiological T doses (dose-dependency analysis). We further hypothesized that we would demonstrate a dose-dependent improvement in cardiometabolic profiles-with improvement in insulin resistance and more favourable adipokine and lipid profiles. As part of our secondary analysis, we also assessed the relationship between these outcomes and serum sex steroid concentrations (T, DHT and E2) as continuous variables, regardless of dose group (concentration-dependency analysis).
| MATERIALS AND METHODS
Presented results are prespecified secondary outcome measures from a previously reported trial designed to explore the effects of varying T doses on intraprostatic androgen concentrations and other prostate outcomes in healthy men. Those results have been published 11 with full details of study procedures, safety laboratory assessments, inclusion/exclusion criteria, statistical methods and adverse events and are summarized briefly below.
| Subjects
We recruited healthy male volunteers, ages 25-55, years via advertisement. Written informed consent was obtained prior to screening.
All study procedures were conducted at the University of Washington Medical Center, Seattle, WA and were approved by the Institutional Review Board. Notable inclusion criteria included general good health, normal serum total T level (>10.4 nmol/L), normal reproductive history and normal physical examination, while exclusion criteria included use of any drugs known to affect steroid hormone synthesis, metabolism or effect in the past 3 months, history of illicit drug or alcohol abuse, weight >145 kg or BMI>40. Ninety-eight subjects were screened; 67
were randomized to receive treatment, but only 62 chose to initiate treatment, and subsequently nine subjects dropped out during the study; 53 completed the week 12 end-of-treatment visit, but three declined the final on-treatment body composition analyses and were excluded from data analysis. Another two subjects were excluded from the analyses due to drug noncompliance (n=48 for analysis).
| Study design and randomization
Subjects were randomly assigned (using random block allocation with block size of 4) to either a 
| Primary outcomes
Body composition (total lean body mass, total fat mass) was assessed by dual-energy X-ray absorptiometry (DXA) scan using a GE Lunar Prodigy scanner at baseline, end-of-treatment and recovery. The DXA scanner is regularly calibrated to ensure accuracy and reproducibility of results, and a single technician performed all of the study measurements. Based on the respective precision errors of 0.25 and 0.15 kg for fat mass and total body mass, the least significant change for each metric was 0.68 and 0.42 kg respectively. Blood was collected every 2 weeks during treatment, and sex steroids were quantified by liquid chromatography-tandem mass spectrometry (LC-MS/MS) as described previously. 13 This assay is validated for T quantification by the CDC using certified standards. The lower limit of quantification for T and DHT was ≤0.035 nmol/L and 7.34 pmol/L for E2. The intra-assay coefficients of variation were <5% for all three sex steroids. Normal reference ranges for serum T and DHT using these methods were established from 118 morning samples from healthy men, ages 18-55.
| Secondary outcomes
Fasting serum lipids and adiponectin, leptin, glucose and insulin concentrations were measured at baseline, week 10 and recovery. These were not measured at end-of-treatment (week 12) as subjects were not fasting at that visit while multiple other study procedures took place.
The homoeostatic model assessment for insulin resistance (HOMA-IR) was calculated from the fasting glucose and insulin concentrations.
14 Serum glucose concentrations were measured enzymatically using Fasting serum lipids (LDL-C, total cholesterol, HDL-C, triglycerides)
were measured by the Northwest Lipid Research Center (Seattle, WA) using standard assays.
15

| Statistical analyses
The original study was powered to identify changes in intraprostatic androgen concentrations as previously described. Bonferroni P-value of <.008 being considered significant. To assess changes within a group during the study, a Wilcoxon signed rank test with an unadjusted P<.05 was considered significant. Spearman's correlation was used to evaluate the associations between serum hormone concentrations and various study end-points. We calculated average on-treatment serum T, DHT and E2 concentrations in all study groups using concentrations measured every 2 weeks from weeks 2-12, to account for intra-individual variability in T concentrations observed with transdermal T gel. 7 The changes in serum T, DHT and E2 concentrations for each subject were calculated by subtracting the baseline (Day 0) value from the average on-treatment value (weeks 2-12). All analyses were performed using GraphPad Prism 6.0 (La Jolla, CA). Intention to treat analysis was not performed, and only subjects that completed the study were included in the analysis.
| RESULTS
| Subjects
Forty-eight subjects were included in the data analysis. There were no significant differences at baseline among subjects in the six treatment groups except in serum adiponectin concentrations (Table 1) .
| Serum hormones
On-treatment serum T ( Figure 1A ), DHT ( Figure 1B ) and E2 ( Figure 1C )
concentrations significantly differed with escalating doses of exogenous T (ANOVA P<.001 for all). Serum T and E2 concentrations ranged from below normal to the higher end of the normal range, while serum DHT concentrations were above the upper limit of the normal range in all but the placebo and lowest dose T groups (1.25 g). The ratio of serum DHT/T was higher in all the treatment groups compared to the placebo group ( Figure 1D) ; however, there was no dose-dependent difference in this ratio between the treatment groups.
| Body Composition
Body weight remained stable in all groups throughout the study (Fig.   S1 ). Absolute change in body fat (kg) was not significantly different across the treatment groups (ANOVA P=.14, Figure 2A ). Although there was no significant intergroup treatment effect on fat mass, subjects in the 1.25 g T group uniformly exhibited increases in fat mass (Wilcoxon matched-pairs signed rank test P=.004) with a median increase of 1.9 kg (IQR 1.1-2.3 kg), as did four of six subjects in the 2.5 g T group, although this did not achieve statistical significance in the group as a whole. In contrast, change in lean mass differed significantly across treatment groups (ANOVA P=.011, Figure 2B ). In we were unable to assess whether changes in body composition were maintained with sufficient, sustained recovery of the gonadal axis.
In our concentration-dependency analysis, change in lean mass exhibited strong correlations with average on-treatment serum T and E2 concentrations ( Figure 3 ) and showed similar, positive correlations with changes in serum T and E2 concentrations (Fig. S2) . In contrast, change in fat mass inversely correlated with on-treatment serum sex steroids with a stronger correlation with serum E2 than T concentration ( Figure 4 ). Change in fat mass also inversely correlated with changes in serum concentrations of T and E2 (Fig. S3) . We also performed a sensitivity analysis by excluding the placebo group in these correlations as this group did not receive any GnRH antagonist or T and so had no net change in sex steroid concentrations, but this did not affect the results for serum T and E2. However, when looking at correlations between change in body composition and average on-treatment ( Figure 5 ) and change in serum DHT ( 
| Lipids
The 
| Metabolic parameters
Changes in fasting glucose and insulin concentrations were not significantly different across the treatment groups (P=.41 and P=.47 in overall ANOVA respectively), nor were there significant within-group changes in either of these parameters. Consistent with this absence of treatment effect, change in HOMA-IR also did not differ by group 
| DISCUSSION
Our findings support a concentration-dependent relationship between serum sex steroids and body composition changes in men.
We achieved a wide range of serum T, E2 and DHT concentrations in healthy young men by suppressing endogenous sex steroid production and administering incremental doses of exogenous T. Serum T and E2 concentrations ranged from below normal to the high-normal range for healthy young men. We found a significant effect of T dose on change in lean mass. Increased lean mass strongly and positively correlated with serum concentrations of all three sex steroids, as these rise in a colinear fashion with transdermal T administration.
Although the overall effect of treatment group was not statistically significant for change in fat mass, increases in fat mass were seen uniformly among subjects receiving the 1.25 g dose of exogenous T.
Moreover, in our concentration-dependency analysis, an inverse correlation between change in fat mass and on-treatment sex steroid concentrations was observed.
Our results are consistent with those of Bhasin et al. 16 who utilized a GnRH agonist and escalating doses of injectable T for 20 weeks.
These investigators noted increases in lean mass in the men receiving supraphysiologic doses of T replacement and a strong, positive correlation between the changes in lean mass and serum T concentrations. They also found no significant effect of T dose on change in fat mass but did report an inverse correlation between changes in fat mass and serum T levels. Notably, in contrast to Bhasin et al., we used transdermal T as compared to intramuscular T, with a shorter study interval and lower overall exposure to T and E2 as a result of both the pharmacokinetics of transdermal gel vs injections and the lower doses of T administered. In addition, these authors did not explore the relationship between serum DHT and body composition in their analyses.
Our findings also are consistent with prior studies that suppressed endogenous sex steroid production in men and administered transdermal T gel in varying doses. 5, 17 Similar to our study design, two prior studies gave healthy, eugonadal men a GnRH antagonist with varying doses of T gel add-back. In these subject cohorts, on-treatment serum T and E2 concentrations were comparable to those achieved in our Further, our results suggest that lean mass continues to increase with a T dose increment from 10 g to 15 g daily, although this intergroup comparison did not reach statistical significance. Finally, findings from both studies suggest that T doses of 5 g daily or more are needed to prevent increases in fat mass in medically castrated healthy men.
Importantly, in both previously published studies, observed changes in fat mass appeared more strongly attributable to changes in serum E2 levels than changes in serum T levels. Our study was not designed to make this distinction, but the results of our correlation analyses are consistent with a role for E2 in the regulation of adiposity in men.
Additionally, we have expanded on these findings by assessing the relationship between serum DHT concentrations and the changes noted in body composition. The inclusion of a double-placebo group, where subjects underwent no changes to their gonadal status, is a strength of this analysis, allowing us to control for body composition and metabolic changes that were purely a function of time.
Although T is considered the dominant circulating androgen in men, serum DHT concentrations may play an important role in some androgen-mediated end-organ effects. Although serum DHT concentrations are 10-100-fold lower than T, DHT is a more potent androgen, binding the androgen receptor with greater affinity than T. While DHT may not be required for androgen-mediated changes in body composition, exogenous DHT (that suppresses endogenous T) supports favourable, androgen-related body composition changes.
One study using 3 months of DHT gel in healthy older men showed that supraphysiologic serum DHT concentrations lowered their fat mass significantly (~2 kg) while not changing lean mass. 23 When used as androgen replacement, transdermal DHT gel decreased fat mass and increased lean mass in hypogonadal middle-aged men. 24 Serum DHT concentrations rise to much higher levels in men receiving TRT by transdermal than by an injectable route, 21 likely due to robust 5α-reductase activity in the skin. Exogenous T administration within the normal physiologic range in healthy young men has not been shown to markedly affect plasma lipid levels, 26 in contrast to anabolic steroid abuse in athletes. 27 Consistent with these findings, we did not find a significant treatment effect in this study on plasma lipid concentrations, nor were significant changes observed within any treatment group during the intervention period.
Despite positive changes in body composition, no changes in fasting insulin, fasting glucose or HOMA-IR were observed in this study. Of note, however, our healthy volunteers were not insulin resistant, markedly obese or hypogonadal at baseline. Consistent with our results, testosterone-mediated changes in insulin sensitivity/resistance are not consistently observed in healthy, young men receiving exogenous T. 26 In contrast, older, hypogonadal men receiving TRT often demonstrate modest improvements in insulin resistance. 28 The difference in the metabolic responses of healthy men compared to hypogonadal men when exposed to exogenous androgens may stem from changes that result from either prolonged hypogonadism or baseline metabolic dysfunction in hypogonadal individuals. Alternatively, the lack of change in insulin resistance we observed in the study presented here may result from insufficient power for these end-points. 
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The primary limitation of our study is its small sample size, which represents the most likely reason a significant treatment group effect was not seen for change in fat mass. However, our study has nota- and DHT in men in contrast to the historical focus on T. Ultimately, this line of investigation has the potential to better define optimal TRT regimens on an individual basis and thereby enable delivery of a therapy that confers the desired androgenic effects while minimizing cardiometabolic risk.
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